Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYRIC: High Dose Cyclophosphamide Post-transplantation for GVHD Prophylaxis
NCT03263767Phase 2Terminated
- Sponsor
- CHU de Nantes
- Start
- Jan 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD) (4 arms), sponsored by CHU de Nantes. Primary endpoint: Incidence of grade 3 and 4 acute GVHD cortico-resistant at 100 days. Started Jan 2018; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03263767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263767.